Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
328 stopped studies mapped to Myelodysplastic Syndrome and descendants · 88% state a reason
Over the 328 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01688011 | Connect® Myeloid Disease Registry | — | terminated | Sep 19, 2012 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT02848001 | A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid… | Phase 1 | terminated | Jul 28, 2016 | Celgene | Trial terminated because of lack of efficacy in the short term acute phase. | Efficacy / futility |
| NCT06572631 | Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for… | Phase 1 | withdrawn | Aug 27, 2024 | City of Hope Medical Center | cprmc withdrawn | Other (stated, no rule matched) |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of… | Phase 1 / Phase 2 | terminated | Feb 12, 2021 | M.D. Anderson Cancer Center | supporting/funding source decided to de-prioritize and stop development of DS-1594 | Funding |
| NCT03286114 | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | Phase 1 | terminated | Sep 18, 2017 | University of Michigan Rogel Cancer Center | Lack of patient population | Other (stated, no rule matched) |
| NCT05766514 | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs.… | Phase 2 | withdrawn | Mar 13, 2023 | University of Florida | Study disapproved by internal scientific review committee on re-review; study will no longer move… | Other (stated, no rule matched) |
| NCT03016130 | Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute… | Phase 3 | terminated | Jan 10, 2017 | University of Florida | Interim analysis determined that study reached a safety stopping rule | Safety / toxicity |
| NCT04477291 | A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | Phase 1 | terminated | Jul 20, 2020 | Aptose Biosciences Inc. | Change in corporate strategy | Sponsor / business decision |
| NCT02291965 | Blood Samples to Identify Biomarkers of Busulfan | — | terminated | Nov 17, 2014 | Fred Hutchinson Cancer Center | Study terminated due to end of funding | Funding |
| NCT04083170 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic… | Phase 2 | terminated | Sep 10, 2019 | Fred Hutchinson Cancer Center | The federal funding period ended. The study was originally intended to be multi-site but was only… | Enrollment / accrual |
| NCT03939585 | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells… | Phase 1 | withdrawn | May 7, 2019 | Leland Metheny | Lack of funding | Funding |
| NCT04762875 | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in… | Phase 2 | terminated | Feb 21, 2021 | Ensoma | This study was voluntarily terminated due to a business decision not to proceed and not due to any… | Safety / toxicity |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Phase 1 | terminated | Mar 21, 2019 | Cyclacel Pharmaceuticals, Inc. | Switch to oral formulation of CYC140 (plogosertib) | Other (stated, no rule matched) |
| NCT05823480 | Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with… | Phase 1 | withdrawn | Apr 21, 2023 | City of Hope Medical Center | Withdrawn -ctms | Other (stated, no rule matched) |
| NCT00522990 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | Phase 1 / Phase 2 | terminated | Aug 30, 2007 | Astex Pharmaceuticals, Inc. | Recommended Phase II dose determined | Other (stated, no rule matched) |
| NCT02520427 | A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies | Phase 1 | terminated | Aug 11, 2015 | Amgen | Amgen strategic business decision to cancel following portfolio review, re-prioritization. | Sponsor / business decision |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | Phase 1 | terminated | Jun 26, 2017 | Roncarolo, Maria Grazia, MD | Lack of Enrollment | Enrollment / accrual |
| NCT03176277 | A Study of ONO-7475 in Patients With Acute Leukemias | Phase 1 / Phase 2 | terminated | Jun 5, 2017 | Ono Pharmaceutical Co., Ltd. | Protocol defined futility criteria | Efficacy / futility |
| NCT03088709 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | Phase 2 | terminated | Mar 23, 2017 | Loyola University | Poor accrual | Enrollment / accrual |
| NCT06337331 | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic… | Phase 2 | withdrawn | Mar 29, 2024 | Northside Hospital, Inc. | Unable to accommodate FDA recommendations for protocol revisions | Other (stated, no rule matched) |
| NCT04526288 | CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade… | Phase 2 | terminated | Aug 25, 2020 | Fred Hutchinson Cancer Center | Terminated due to low accrual | Enrollment / accrual |
| NCT03175978 | IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome | Phase 1 / Phase 2 | terminated | Jun 5, 2017 | IGF Oncology, LLC | Funding | Funding |
| NCT00346632 | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and… | Phase 1 | terminated | Jun 30, 2006 | Kyowa Kirin, Inc. | Terminated due to suboptimal dosing schedule | Other (stated, no rule matched) |
| NCT02181699 | Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic… | Phase 1 | terminated | Jul 4, 2014 | Kyowa Kirin, Inc. | Failed treatment response | Other (stated, no rule matched) |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the… | Phase 1 / Phase 2 | withdrawn | Jun 8, 2023 | Indiana University | PI has left IU with no plan to initiate study at IU | Other (stated, no rule matched) |
| NCT05367401 | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS… | Phase 1 / Phase 2 | withdrawn | May 10, 2022 | Novartis Pharmaceuticals | waiting for update from Study Lead | Other (stated, no rule matched) |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT04912063 | Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used… | Phase 1 | terminated | Jun 3, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02841540 | A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes(Encore-MDS) | Phase 1 | terminated | Jul 22, 2016 | Hemavant Sciences GmbH | The study was terminated after conducting an interim analysis of the available data where it became… | Efficacy / futility |
| NCT02508324 | IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During… | Phase 2 | terminated | Jul 24, 2015 | Weill Medical College of Cornell University | Slow accrual and change in direction of cord blood program | Enrollment / accrual |
| NCT05829434 | Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS(MAGROLIC) | Phase 2 | withdrawn | Apr 25, 2023 | Uwe Platzbecker | Trial was stopped prematurely due to safety reasons | Safety / toxicity |
| NCT05168904 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic… | Phase 1 / Phase 2 | suspended | Dec 23, 2021 | Cyclacel Pharmaceuticals, Inc. | Slow enrollment and financial limitations | Enrollment / accrual |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI)… | Phase 1 / Phase 2 | withdrawn | Jan 21, 2022 | Naoyuki G. Saito, M.D., Ph.D. | insufficient staff and updates in standard practice have made it difficult to recruit participants | Enrollment / accrual |
| NCT04361058 | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With… | Phase 1 | withdrawn | Apr 24, 2020 | SCRI Development Innovations, LLC | The single site that was deemed appropriate for this study was unable to enroll patients. Closed… | Enrollment / accrual |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem… | Phase 1 / Phase 2 | terminated | Oct 8, 2007 | City of Hope Medical Center | Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than… | Enrollment / accrual |
| NCT03593915 | A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS | Phase 1 / Phase 2 | terminated | Jul 20, 2018 | Sumitomo Pharma America, Inc. | The sponsor decided not to continue the study based on the overall company strategy in AML. | Sponsor / business decision |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or… | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | Bellicum Pharmaceuticals | company decision | Sponsor / business decision |
| NCT04166929 | Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS(Bigeminy) | Phase 2 | terminated | Nov 18, 2019 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | low recruitment | Enrollment / accrual |
| NCT02065869 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | Phase 1 / Phase 2 | terminated | Feb 19, 2014 | Bellicum Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT03699475 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide…(THRIVE) | Phase 2 / Phase 3 | terminated | Oct 9, 2018 | Bellicum Pharmaceuticals | Funding, portfolio re-prioritization | Funding |
| NCT03733249 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | Phase 1 / Phase 2 | terminated | Nov 7, 2018 | Bellicum Pharmaceuticals | not stated | Not stated |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT00816413 | Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients… | Phase 1 / Phase 2 | withdrawn | Jan 1, 2009 | University of Nebraska | Screenings yielded inadequate eligible subjects to enroll. | Enrollment / accrual |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients… | Early Phase 1 | terminated | Sep 5, 2017 | Rutgers, The State University of New Jersey | Lack of enrollment | Enrollment / accrual |
| NCT04631211 | Thrombosomes® in Bleeding Thrombocytopenic Patients Study | Phase 2 | terminated | Nov 17, 2020 | Cellphire Therapeutics, Inc. | This study was terminated due to loss of funding for this indication from the Biomedical Advanced… | Funding |
| NCT03233074 | Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML…(COSMOS) | — | terminated | Jul 28, 2017 | Centre Hospitalier Universitaire de Saint Etienne | Achievement of scientific objectives | Other (stated, no rule matched) |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected… | Phase 1 | terminated | Mar 14, 2018 | Amgen | Strategic decisions | Sponsor / business decision |
| NCT02863458 | DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies… | — | withdrawn | Aug 11, 2016 | The Cleveland Clinic | Study was a data review, no patient recruitment occurred. | Enrollment / accrual |
| NCT04326764 | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | Phase 3 | terminated | Mar 30, 2020 | Goethe University | Change of marketing authorisation holder | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 3, 2025source: clinicaltrials